Bray GARisks of obesity. Endocrinol Metab Clin N Am2003;32:787-804.
2.
Williams KV, Kelley DEMetabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes. Diabetes Obes Metab2000 ;2:121-9.
3.
Norris SL, Zhang X., Avenell A. et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. A meta-analysis. Arch Intern Med2004;164:1395-404.
4.
Di Marzo V., Bifulco M., De Petrocellis L.The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov2004;3:771-84.
5.
Van Gaal LF, Rissanen AM, Scheen AJ et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 year experience from the RIO-Europe study. Lancet2005;365:1389-97.
6.
Despres JP, Golay A., Sjostrom L. et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med2005 ;353:2121-34.
7.
Scheen AJRimonabant in overweight and obese type 2 diabetes. American Diabetes Association. 65th annual Scientific Sessions: Abstract 7-LB. Presented 12 June 2005.
